Open label, single center pilot proof of concept study to assess a combination of orlistat, simethicome and activated charcoal in ameliorating the gastrointestinal adverse effects compared to orlistat taken alone as a single medication

Trial Profile

Open label, single center pilot proof of concept study to assess a combination of orlistat, simethicome and activated charcoal in ameliorating the gastrointestinal adverse effects compared to orlistat taken alone as a single medication

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Orlistat (Primary) ; Charcoal; Simethicone
  • Indications Obesity
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 20 Sep 2016 New trial record
    • 29 Aug 2016 Results published in M Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top